Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.

Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to assess the efficacy and safety of adding clopidogrel to aspirin on stroke prevention in high vascular risk patients, and to provide e...

Full description

Bibliographic Details
Main Authors: Shuying Chen, Qingyu Shen, Yamei Tang, Lei He, Yi Li, Hui Li, Mei Li, Ying Peng
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4128803?pdf=render
id doaj-c54652bed7064eb8ac332bbe4bbed463
record_format Article
spelling doaj-c54652bed7064eb8ac332bbe4bbed4632020-11-24T22:11:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10440210.1371/journal.pone.0104402Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.Shuying ChenQingyu ShenYamei TangLei HeYi LiHui LiMei LiYing PengWhether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to assess the efficacy and safety of adding clopidogrel to aspirin on stroke prevention in high vascular risk patients, and to provide evidence for a suitable duration of dual antiplatelet therapy.We searched PubMed, EMBase, OVID and Cochrane Central Register of Controlled Trials (up to June, 2013) for randomized controlled trials evaluating the efficacy and safety of clopidogrel plus aspirin versus aspirin alone in high vascular risk patients. Comparisons of stroke and hemorrhagic complications between treatment groups were expressed by the pooled Relative Risks (RRs) with 95% Confidence Intervals (CIs).Fifteen trials with a total of 97692 intention-to-treat participants were included with duration of follow-up ranging from 7 days to 3.6 years. Dual antiplatelet therapy reduced all stroke by 21% (RR: 0.79, 95% CI: 0.73-0.85) with no evidence of heterogeneity across the trials (P = 0.27, I2 = 17%).The effects were consistent between short-term subgroup (≤1 month, RR: 0.76, 95% CI: 0.67-0.85) and long-term subgroup (≥3 months, RR: 0.81, 95% CI: 0.73-0.89). The risk of major bleeding was not significantly increased by dual antiplatelet therapy in short-term subgroup (RR: 1.11, 95% CI: 0.91-1.36), while significantly increased in long-term subgroup (RR: 1.52, 95% CI: 1.36-1.69). Long-term dual antiplatelet therapy substantially increased the risk of intracranial bleeding (RR: 1.76, 95% CI: 1.22-2.54).This meta-analysis demonstrates that short-term combination of clopidogrel and aspirin is effective and safe for stroke prevention in high vascular risk patients. Long-term combination therapy substantially increases the risk of major bleeding and intracranial bleeding.http://europepmc.org/articles/PMC4128803?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Shuying Chen
Qingyu Shen
Yamei Tang
Lei He
Yi Li
Hui Li
Mei Li
Ying Peng
spellingShingle Shuying Chen
Qingyu Shen
Yamei Tang
Lei He
Yi Li
Hui Li
Mei Li
Ying Peng
Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
PLoS ONE
author_facet Shuying Chen
Qingyu Shen
Yamei Tang
Lei He
Yi Li
Hui Li
Mei Li
Ying Peng
author_sort Shuying Chen
title Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
title_short Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
title_full Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
title_fullStr Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
title_full_unstemmed Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
title_sort efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to assess the efficacy and safety of adding clopidogrel to aspirin on stroke prevention in high vascular risk patients, and to provide evidence for a suitable duration of dual antiplatelet therapy.We searched PubMed, EMBase, OVID and Cochrane Central Register of Controlled Trials (up to June, 2013) for randomized controlled trials evaluating the efficacy and safety of clopidogrel plus aspirin versus aspirin alone in high vascular risk patients. Comparisons of stroke and hemorrhagic complications between treatment groups were expressed by the pooled Relative Risks (RRs) with 95% Confidence Intervals (CIs).Fifteen trials with a total of 97692 intention-to-treat participants were included with duration of follow-up ranging from 7 days to 3.6 years. Dual antiplatelet therapy reduced all stroke by 21% (RR: 0.79, 95% CI: 0.73-0.85) with no evidence of heterogeneity across the trials (P = 0.27, I2 = 17%).The effects were consistent between short-term subgroup (≤1 month, RR: 0.76, 95% CI: 0.67-0.85) and long-term subgroup (≥3 months, RR: 0.81, 95% CI: 0.73-0.89). The risk of major bleeding was not significantly increased by dual antiplatelet therapy in short-term subgroup (RR: 1.11, 95% CI: 0.91-1.36), while significantly increased in long-term subgroup (RR: 1.52, 95% CI: 1.36-1.69). Long-term dual antiplatelet therapy substantially increased the risk of intracranial bleeding (RR: 1.76, 95% CI: 1.22-2.54).This meta-analysis demonstrates that short-term combination of clopidogrel and aspirin is effective and safe for stroke prevention in high vascular risk patients. Long-term combination therapy substantially increases the risk of major bleeding and intracranial bleeding.
url http://europepmc.org/articles/PMC4128803?pdf=render
work_keys_str_mv AT shuyingchen efficacyandsafetyofaddingclopidogreltoaspirinonstrokepreventionamonghighvascularriskpatientsametaanalysisofrandomizedcontrolledtrials
AT qingyushen efficacyandsafetyofaddingclopidogreltoaspirinonstrokepreventionamonghighvascularriskpatientsametaanalysisofrandomizedcontrolledtrials
AT yameitang efficacyandsafetyofaddingclopidogreltoaspirinonstrokepreventionamonghighvascularriskpatientsametaanalysisofrandomizedcontrolledtrials
AT leihe efficacyandsafetyofaddingclopidogreltoaspirinonstrokepreventionamonghighvascularriskpatientsametaanalysisofrandomizedcontrolledtrials
AT yili efficacyandsafetyofaddingclopidogreltoaspirinonstrokepreventionamonghighvascularriskpatientsametaanalysisofrandomizedcontrolledtrials
AT huili efficacyandsafetyofaddingclopidogreltoaspirinonstrokepreventionamonghighvascularriskpatientsametaanalysisofrandomizedcontrolledtrials
AT meili efficacyandsafetyofaddingclopidogreltoaspirinonstrokepreventionamonghighvascularriskpatientsametaanalysisofrandomizedcontrolledtrials
AT yingpeng efficacyandsafetyofaddingclopidogreltoaspirinonstrokepreventionamonghighvascularriskpatientsametaanalysisofrandomizedcontrolledtrials
_version_ 1725804557035896832